PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Pharmanutra S.p.A. (PHN.MI)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

IT0005274094

Sector

Healthcare

Highlights

Market Cap

€547.65M

EPS (TTM)

€1.51

PE Ratio

37.75

Total Revenue (TTM)

€84.50M

Gross Profit (TTM)

€30.79M

Year Range

€44.85 - €62.46

Target Price

€80.30

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of €10,000 in Pharmanutra S.p.A., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


0.00%5.00%10.00%15.00%20.00%SeptemberOctoberNovemberDecember2025February
4.09%
17.59%
PHN.MI (Pharmanutra S.p.A.)
Benchmark (^GSPC)

Returns By Period

Pharmanutra S.p.A. had a return of -6.43% year-to-date (YTD) and -17.60% in the last 12 months.


PHN.MI

YTD

-6.43%

1M

-1.36%

6M

4.09%

1Y

-17.60%

5Y*

18.02%

10Y*

N/A

^GSPC (Benchmark)

YTD

2.90%

1M

3.70%

6M

10.94%

1Y

22.18%

5Y*

12.41%

10Y*

11.21%

*Annualized

Monthly Returns

The table below presents the monthly returns of PHN.MI, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-6.43%-6.43%
202410.28%-4.18%-4.36%-6.32%-6.24%-3.45%-0.32%14.14%7.76%-6.17%1.10%-1.63%-1.95%
2023-5.62%2.04%-7.33%-9.35%18.29%3.41%-4.28%-5.34%-10.91%-1.53%5.91%10.37%-8.05%
2022-12.47%-4.85%0.32%3.02%2.98%-8.77%11.28%0.89%-2.07%2.26%-6.05%-2.20%-16.46%
20210.27%-3.98%3.59%-1.87%-0.36%36.67%7.32%24.24%-4.88%8.97%4.41%6.20%104.25%
2020-0.43%-5.15%-0.45%10.00%3.16%-4.90%-0.43%-0.86%15.22%0.75%6.74%31.93%63.73%
201911.92%0.30%0.30%1.76%10.91%8.90%-5.29%3.05%-2.22%2.77%10.78%3.54%55.68%
2018-3.54%4.90%2.72%2.27%2.11%7.06%5.90%0.33%0.65%0.65%0.97%-3.51%21.85%
2017-4.72%-4.73%5.12%-4.05%-2.03%1.19%-9.22%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of PHN.MI is 15, meaning it’s performing worse than 85% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of PHN.MI is 1515
Overall Rank
The Sharpe Ratio Rank of PHN.MI is 1212
Sharpe Ratio Rank
The Sortino Ratio Rank of PHN.MI is 1212
Sortino Ratio Rank
The Omega Ratio Rank of PHN.MI is 1414
Omega Ratio Rank
The Calmar Ratio Rank of PHN.MI is 2020
Calmar Ratio Rank
The Martin Ratio Rank of PHN.MI is 1919
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Pharmanutra S.p.A. (PHN.MI) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for PHN.MI, currently valued at -0.68, compared to the broader market-2.000.002.004.00-0.681.59
The chart of Sortino ratio for PHN.MI, currently valued at -0.93, compared to the broader market-6.00-4.00-2.000.002.004.00-0.932.16
The chart of Omega ratio for PHN.MI, currently valued at 0.89, compared to the broader market0.501.001.502.000.891.29
The chart of Calmar ratio for PHN.MI, currently valued at -0.44, compared to the broader market0.002.004.006.00-0.442.40
The chart of Martin ratio for PHN.MI, currently valued at -1.10, compared to the broader market0.0010.0020.0030.00-1.109.79
PHN.MI
^GSPC

The current Pharmanutra S.p.A. Sharpe ratio is -0.68. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Pharmanutra S.p.A. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00SeptemberOctoberNovemberDecember2025February
-0.68
1.86
PHN.MI (Pharmanutra S.p.A.)
Benchmark (^GSPC)

Dividends

Dividend History

Pharmanutra S.p.A. provided a 1.67% dividend yield over the last twelve months, with an annual payout of €0.85 per share. The company has been increasing its dividends for 5 consecutive years.


0.50%1.00%1.50%2.00%€0.00€0.20€0.40€0.60€0.802018201920202021202220232024
Dividends
Dividend Yield
PeriodTTM2024202320222021202020192018
Dividend€0.85€0.85€0.80€0.71€0.67€0.46€0.08€0.33

Dividend yield

1.67%1.56%1.42%1.14%0.89%1.22%0.34%2.19%

Monthly Dividends

The table displays the monthly dividend distributions for Pharmanutra S.p.A.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025€0.00€0.00€0.00
2024€0.00€0.00€0.00€0.00€0.85€0.00€0.00€0.00€0.00€0.00€0.00€0.00€0.85
2023€0.00€0.00€0.00€0.00€0.80€0.00€0.00€0.00€0.00€0.00€0.00€0.00€0.80
2022€0.00€0.00€0.00€0.00€0.71€0.00€0.00€0.00€0.00€0.00€0.00€0.00€0.71
2021€0.00€0.00€0.00€0.00€0.67€0.00€0.00€0.00€0.00€0.00€0.00€0.00€0.67
2020€0.00€0.00€0.00€0.00€0.46€0.00€0.00€0.00€0.00€0.00€0.00€0.00€0.46
2019€0.00€0.00€0.00€0.00€0.08€0.00€0.00€0.00€0.00€0.00€0.00€0.00€0.08
2018€0.33€0.00€0.00€0.00€0.00€0.00€0.00€0.00€0.33

Dividend Yield & Payout


Dividend Yield
5.0%10.0%15.0%20.0%1.7%
Pharmanutra S.p.A. has a dividend yield of 1.67%, which is quite average when compared to the overall market.
Payout Ratio
200.0%400.0%600.0%800.0%68.2%
Pharmanutra S.p.A. has a payout ratio of 68.23%, which is quite average when compared to the overall market. This suggests that Pharmanutra S.p.A. strikes a balance between reinvesting profits for growth and paying dividends to shareholders.

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-40.00%-30.00%-20.00%-10.00%0.00%SeptemberOctoberNovemberDecember2025February
-32.74%
-1.03%
PHN.MI (Pharmanutra S.p.A.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Pharmanutra S.p.A.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Pharmanutra S.p.A. was 40.99%, occurring on Oct 9, 2023. The portfolio has not yet recovered.

The current Pharmanutra S.p.A. drawdown is 32.74%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-40.99%Jan 6, 2022450Oct 9, 2023
-32.11%Jan 14, 202048Mar 19, 202033May 8, 202081
-14.08%Sep 6, 202120Oct 1, 202121Nov 1, 202141
-13.87%Jul 19, 2017147Feb 14, 201863May 17, 2018210
-11.5%Dec 28, 202054Mar 15, 202160Jun 9, 2021114

Volatility

Volatility Chart

The current Pharmanutra S.p.A. volatility is 4.74%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%4.00%6.00%8.00%10.00%12.00%14.00%SeptemberOctoberNovemberDecember2025February
4.74%
4.05%
PHN.MI (Pharmanutra S.p.A.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Pharmanutra S.p.A. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Pharmanutra S.p.A..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab